Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Humacyte Inc (NQ: HUMA ) 5.050 -0.100 (-1.94%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Humacyte Inc < Previous 1 2 3 4 5 Next > HUMACYTE ALERT: Bragar Eagel & Squire, P.C. is Investigating Humacyte, Inc. on Behalf of Humacyte Stockholders and Encourages Investors to Contact the Firm October 24, 2024 From Bragar Eagel & Squire Via GlobeNewswire Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Humacyte, Inc. (HUMA) October 23, 2024 From Kirby McInerney LLP Via Business Wire Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Humacyte, Inc. (HUMA) on Behalf of Investors October 23, 2024 From Glancy Prongay & Murray LLP Via Business Wire (HUMA) - Analyzing Humacyte's Short Interest October 21, 2024 Via Benzinga How Is The Market Feeling About Humacyte? September 05, 2024 Via Benzinga How Is The Market Feeling About Humacyte? August 19, 2024 Via Benzinga INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Humacyte, Inc. (HUMA) on Behalf of Investors October 22, 2024 From Law Offices of Howard G. Smith Via Business Wire The Law Offices of Frank R. Cruz Announces Investigation of Humacyte, Inc. (HUMA) on Behalf of Investors October 22, 2024 From The Law Offices of Frank R. Cruz Via Business Wire InvestorNewsBreaks – EF Hutton Serves as Placement Agent to Humacyte Inc.’s (NASDAQ: HUMA) $30M RDO October 22, 2024 Via Investor Brand Network Kaplan Fox & Kilsheimer LLP is Investigating Humacyte, Inc. (HUMA) for Potential Securities Law Violations October 22, 2024 Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. Via NewMediaWire Exposures Product Safety Unpacking the Latest Options Trading Trends in Humacyte August 12, 2024 Via Benzinga (HUMA) - Analyzing Humacyte's Short Interest July 15, 2024 Via Benzinga Peering Into Humacyte's Recent Short Interest June 26, 2024 Via Benzinga Kaplan Fox & Kilsheimer LLP is Investigating Humacyte, Inc. (HUMA) for Potential Securities Law Violations October 22, 2024 NEW YORK - (NewMediaWire) - October 22, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA). Via TheNewswire.com Exposures Product Safety Humacyte Is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP October 21, 2024 Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. Via NewMediaWire Exposures Product Safety Humacyte Is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP October 21, 2024 NEW YORK - (NewMediaWire) - October 21, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA). Via TheNewswire.com Exposures Product Safety Kaplan Fox & Kilsheimer LLP is Investigating Potential Securities Law Violations Against Humacyte, Inc. (HUMA) October 19, 2024 Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. Via NewMediaWire Exposures Product Safety Kaplan Fox & Kilsheimer LLP is Investigating Potential Securities Law Violations Against Humacyte, Inc. (HUMA) October 19, 2024 NEW YORK, NY - (NewMediaWire) - October 19, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA). Via TheNewswire.com Exposures Product Safety 12 Health Care Stocks Moving In Thursday's After-Market Session October 17, 2024 Via Benzinga HUMA Stock Earnings: Humacyte Misses EPS for Q2 2024 August 13, 2024 HUMA stock results show that Humacyte missed analyst estimates for earnings per share the second quarter of 2024. Via InvestorPlace Delay Hits Humacyte's Bioengineered Human Tissue Implant For Vascular Trauma Injuries, FDA Extends Time To Review August 12, 2024 FDA extends review timeline for Humacyte's FDA marketing application for its acellular tissue-engineered vessel in vascular trauma. Originally set for August 2024, the new action date remains... Via Benzinga Exposures Product Safety Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday August 12, 2024 It's time to dive into the biggest pre-market stock movers for Monday morning with all of the latest news affecting shares today! Via InvestorPlace Why Ainos Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket August 12, 2024 Via Benzinga 8 Best-Performing Small Caps In July: Find Out Which Stock Jumped 803% August 01, 2024 Macro environment favors large-caps, but July saw impressive gains for small-caps, with Serve Robotics leading at 803% and Q32 Bio at 101%. Via Benzinga Three Small-Cap Stocks to Buy Before a September-Rate-Cut Rally July 18, 2024 Discover three small-cap stocks to buy before the Fed acts on interest rates as these small-cap stocks will utilize any cuts to multiply. Via InvestorPlace Topics Economy Exposures Interest Rates What's Going On With Huamacyte Shares Tuesday? July 16, 2024 Humacyte has so far added Dr. John P. Bamforth and Dr. Keith Anthony to its Board of Directors, entered a license agreement with Pluristyx and received Regenerative Medicine Advanced Therapy (RMAT)... Via Benzinga Exposures Product Safety Why SolarEdge Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session July 15, 2024 Via Benzinga MicroStrategy, Coinbase, Robinhood, Tesla And Other Big Stocks Moving Higher On Monday July 15, 2024 Via Benzinga Pluristyx Announces License Agreement with Humacyte to Develop BioVascular Pancreas using iPSCs July 09, 2024 From Pluristyx Via Business Wire Why Humacyte Stock Is Trading 15% Higher Monday July 01, 2024 Humacyte received the Food and Drug Administration's Regenerative Medicine Advanced Therapy designation for its Acellular Tissue Engineered Vessel. Via Benzinga < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
